J Thorac Oncol: Efficacy and safety of Durvalumab + tremelimumab combined with or without chemotherapy in the first-line treatment of metastatic NSCLC patients with negative driver genes

Gene driven negative metastatic NSCLC patient comprising a first-line treatment of immune checkpoint inhibitor monotherapy, or double immunized checkpoint inhibitors in combination with chemotherapy
.

Recently, a study was published in the journal J Thorac Oncol, comparing the efficacy and safety of durvalumab + tremelimumab combined with or without chemotherapy in the first-line treatment of metastatic NSCLC patients with negative driver genes

Gene driven negative metastatic NSCLC patient comprising a first-line treatment of immune checkpoint inhibitor monotherapy, or double immunized checkpoint inhibitors in combination with chemotherapy

This is an open-label, randomized phase II clinical study (NCT03057106 ) conducted in 44 centers in Canada and Australia .
Patients with EGFR or ALK-negative metastatic NSCLC were randomly (1:1) to receive durvalumab + tremelimumab with or without platinum dual-drug chemotherapy .
The primary endpoint is overall survival (OS), and the secondary endpoints are progression-free survival (PFS), overall response rate (ORR), and safety .

This is an open-label, randomized phase II clinical study (NCT03057106 ) conducted in 44 centers in Canada and Australia .

Patients with EGFR or ALK-negative metastatic NSCLC were randomly (1:1) to receive durvalumab + tremelimumab with or without platinum dual-drug chemotherapy .
The primary endpoint is overall survival (OS), and the secondary endpoints are progression-free survival (PFS), overall response rate (ORR), and safety .
The primary endpoint is overall survival (OS), and the secondary endpoints are progression-free survival (PFS), overall response rate (ORR), and safety

From February 15, 2017 to November 7, 2018, a total of 301 patients were enrolled, of which durvalumab + tremelimumab combined chemotherapy had 151 cases, and durvalumab + tremelimumab had 150 patients

As of December 1, 2019, the median follow-up time was 16.

As of December 1, 2019, 235 patients had progressed or died, including 108 patients (72%) in the chemotherapy combined immunotherapy group and 127 (85%) in the immunotherapy group
.

Compared with immunotherapy alone (3.

As of December 1, 2019, 235 patients had progressed or died, including 108 patients (72%) in the chemotherapy combined immunotherapy group and 127 (85%) in the immunotherapy group

As of December 1, 2019, the remission rate of the chemotherapy combined immunotherapy group was 42.
4%, and the remission rate of the immunotherapy group was 29.
3% (OR=1.
69, 95% CI 1.
04-2.
76)
.

The duration of remission was similar in the two treatment groups.

As of December 1, 2019, the remission rate of the chemotherapy combined immunotherapy group was 42.

The incidence of ≥ grade 3 adverse events in the chemotherapy combined with immunotherapy group was 82% , while that in the immunotherapy group was 70%

              Explore the influence of TMB and PD-L1 on the prognosis of treatment

Explore the influence of TMB and PD-L1 on the prognosis of treatment

In summary, studies have shown that in the first-line treatment of driver gene-negative advanced NSCLC, the combination of durvalumab + tremelimumab and platinum-based chemotherapy cannot improve the prognosis of patients
.

In summary, studies have shown that in the first-line treatment of
driver gene-negative advanced NSCLC, the combination of durvalumab + tremelimumab and platinum-based chemotherapy cannot improve the prognosis of patients .

In summary, studies have shown that driver gene-negative late-stage studies have shown that driver gene-negative late-stage studies have shown that in the first-line treatment of

Original source:

Leighl NB, Laurie SA, Goss GD, et al.
CCTG BR34: A randomized phase II trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with metastatic non-small cell lung cancer.
J Thorac Oncol.
2021 Nov 17: S1556-0864(21)03322-0.
doi: 10.
1016/j.
jtho.
2021.
10.
023.
Epub ahead of print.
PMID: 34800700.

Leighl NB, Laurie SA, Goss GD, et al.
CCTG BR34: A randomized phase II trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with metastatic non-small cell lung cancer.
J Thorac Oncol.
2021 Nov 17: S1556-0864(21)03322-0.
doi: 10.
1016/j.
jtho.
2021.
10.
023.
Epub ahead of print.
PMID: 34800700.
Leave a message here